Aino Kivikallio

Aino Kivikallio

Auto-generated profile, based on publicly available information

Aino Kivikallio

Institute of Biomedicine and Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2025 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
AKAino Kivikallio
Aino Kivikallio
SMSimona Malaspina
Simona Malaspina
ISIrena Saarinen
Irena Saarinen
MSMarko Seppänen
Marko Seppänen
MAMikael Anttinen
Mikael Anttinen
PTPekka Taimen
Pekka Taimen
Purpose: To prospectively compare the ability of 18F-PSMA-1007 PET/CT and whole-body MRI (WBMRI) with DWI to detect prostate cancer (PCa) lesions and assess their local stage. Additionally, to evaluate the correlation between PSMA uptake on PET/CT and PSMA expression as assessed by immunohistochemistry. Methods: Men with newly diagnosed unfavourable intermediate or high-risk PCa underwent 18F-PSMA-1007 PET/CT and WBMRI with DWI before robot-assisted laparoscopic prostatectomy. Diagnostic accuracy for intraprostatic tumour localization, seminal vesicle invasion (SVI), and extraprostatic extension (EPE) was evaluated using whole-mount prostatectomy specimens as the reference standard. SUVmax was compared with immunohistochemical PSMA staining intensity quantified using QuPath software. Results: 19 patients with 39 intraprostatic lesions in histopathology were included. The overall lesion detection rates for PET/CT were 84.6% and 82.1% for two independent readers, compared to 74.4% and 46.2% for MRI readers. The detection rates of index lesions were 94.7% for PET/CT and 74.0–84.0% for MRI, whereas those of non-index lesions were 70.0–75.0% for PET/CT and 20.0–65.0% for MRI. For detecting EPE, AUC values were 0.500-0.591 for PET/CT and 0.648–0.682 for MRI. For detecting SVI, AUC values ranged from 0.629 to 0.700 across both modalities. SUVmax showed a weak correlation with immunohistochemical expression of PSMA multiplied by lesion diameter (Spearman’s ρ = 0.427, p = 0.013). Lesion diameters measured using 30% and 40% of SUVmax, as well as prostate SUVbackground x2, showed the closest agreement with histopathological measurements. Conclusion: 18F-PSMA-1007 PET/CT demonstrated high sensitivity in localizing intraprostatic carcinoma lesions but seemed inferior to WBMRI in detecting EPE. PSMA uptake appears to depend on both PSMA expression and lesion size. These findings highlight the complementary roles of PET/CT and MRI in the detection and tumor staging of PCa. Clinical trial registration: Clinicaltrials.gov ID: NCT03537391. Registered 25 May 2018.

13 November 2026 in Pediatric and Developmental Pathology
Verified
Journal Article
Open access
AKAino Kivikallio
Aino Kivikallio
AKAndreina Kero
Andreina Kero
TLTiina Laurikainen
Tiina Laurikainen
JMJanna-Maija Mattila
Janna-Maija Mattila
AAAnita Arola
Anita Arola
JLJukka Laine
Jukka Laine
Congenital pulmonary lymphangiectasis (CPL) is a rare developmental disorder characterized by the dilatation of the lymphatics of the lung. CPL can occur in a primary or secondary setting and has been reported in various genetic syndromes. Here, we describe a newborn with fatal CLP together with Beckwith-Wiedemann syndrome (BWS). The newborn presented with cyanosis soon after birth and died at the age of 3.5 hours due to severe hypoxemia leading to acidosis and cardiac dysfunction. Pathological examination revealed severe CLP as well as adrenal and pancreatic findings suggestive of BWS. The latter diagnosis was confirmed via methylation analysis, as the infant showed a sporadic maternal loss of methylation of IC2. To our knowledge, CPL has previously not been reported with BWS.